ABBV Stock Price Today (September 2026) — AbbVie Inc. Analysis & Key Metrics 2026-09-04
AbbVie Inc. (ABBV) is trading at $256.46, down 1.44% today (as of September 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $276.59 (7.8% upside).
- Volatility remains elevated (20.92% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (10.20% YoY) alongside significant competitive pressures.
ABBV Stock Analysis: Key Metrics & Valuation (September 2026)
Concise, actionable data for investors
AbbVie Inc. - Historical Price & Volume
Market Cap
Enterprise Value: $515.83B
P/E Ratio
Forward P/E: 15.75
Revenue Growth
Year over Year
Analyst Target
+7.8% upside potential
Key Investor Questions About ABBV
What investors need to know before buying
Based on current market data, ABBV presents a neutral technical setup with mixed signals fundamentals.
- Technicals say: Neutral (RSI 48.55)
- Fundamentals say: Mixed signals (nuanced financial profile)
ABBV's growth trajectory depends on its ability to expand within the Drug Manufacturers - General sector while managing margin pressures.
- Future growth will depend on performance in core Drug Manufacturers - General operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for ABBV investors include debt exposure and competitive dynamics in the Drug Manufacturers - General industry.
- $70.88B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Drug Manufacturers - General.
52-Week Trading Range
Over the past year, ABBV stock traded between $190.75 and $267.47—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 20.92% annualized volatility and β=0.33, the stock exhibits low sensitivity to market moves—making ABBV suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Plastic surgery is booming with boomers. Here’s how to cash in on the antiaging craze.
Americans age 65 and older are suddenly the fastest-growing customers for cosmetic surgery.
3 Dividend Stocks to Buy and Hold Forever (Including 1 Dividend King)
Owning these dividend stocks could be a simple way to make money over the long term.
ANI Pharmaceuticals (ANIP) Appoints Henry Gosebruch To Its Board
ANI Pharmaceuticals (NasdaqGM: ANIP) appointed biotechnology executive Henry Gosebruch to its Board of Directors. Gosebruch previously held leadership roles at Lakefront Biotherapeutics, Neumora Therapeutics, and AbbVie. Board member Muthusamy (Samy) Shanmugam resigned from the Board and will continue in key operational roles at ANI Pharmaceuticals. This kind of board refresh is not unique to ANI Pharmaceuticals, and investors who want broader exposure to companies shaped closely by their...
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie's immunology pivot is offsetting Humira's decline, while Pfizer trades at half the valuation despite patent risks ahead.
Was JNJ Stock Rally Actually Its Own?
Johnson & Johnson (JNJ) stock returned 59.9% over the past year, against 21.1% for the S&P 500. The company has a clean story for it. The biosimilar hit it had been bracing for arrived and was absorbed, and its talc litigation now has a proposed ending. Both are real. The first does not explain a move that size, and the second is not finished.
Lilly (LLY) Down 2.7% Since Last Earnings Report: Can It Rebound?
Lilly (LLY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ABBV's Etentamig Meets Goals in Phase III Multiple Myeloma Study
AbbVie's etentamig meets key phase III goals in multiple myeloma, improving response rates and progression-free survival versus standard therapies.
AbbVie’s Humira Cash Cow Is Shrinking—Can Its Dividend Keep Growing?
AbbVie's flagship drug is bleeding revenue quarter after quarter, yet the company just handed shareholders another raise. Find out whether the cash machine holding this payout together can survive the patent reckoning already underway.
The Zacks Analyst Blog Highlights Amazon.com, AbbVie, Alibaba and Lulu's Fashion Lounge
Amazon's diversified growth and AI push, AbbVie's pipeline, Alibaba's cloud gains and Lulu's improving margins shape these analyst picks.
Here Are 5 ETFs That Retirees Use to Skip Stock Picking Entirely
Owning two or three dividend ETFs feels like extra protection, but it can quietly leave retirees paying multiple expense ratios for a nearly identical stack of stocks. Here is how the five most popular options actually differ, and why the wrong combination costs more than most people realize.
Explore More Analysis for ABBV
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Frequently Asked Questions
Common investor questions about AbbVie Inc.
AbbVie Inc. (ABBV) is currently trading at $256.46. The RSI (14-day) is at 48.6, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $276.59 implies 7.8% upside from current levels. Volatility is moderate at 20.9% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for AbbVie Inc. (ABBV): The trailing P/E ratio is 72.24, which is above the market average, indicating investors are pricing in higher growth expectations. The forward P/E is 15.75, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 0.42, below 1.0, which generally indicates the stock is undervalued relative to its growth rate. Price-to-Book is -76.34. Price-to-Sales is 7.04. Valuation should be compared to Drug Manufacturers - General industry peers for context, as different sectors trade at different multiples.
Based on 29 analysts covering ABBV, the consensus price target is $276.59. This represents a 7.8% upside from the current price of $256.46. The range spans from a low target of $200.00 to a high target of $328.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, AbbVie Inc. (ABBV) pays a dividend with a current yield of approximately 2.70%. The annualized dividend rate is $6.83 per share. The payout ratio is 190.4%, which exceeds 100%—this means the company is paying out more than it earns, which may not be sustainable long-term. The most recent ex-dividend date was 2026-07-15T00:00:00.000Z.
Key risks for AbbVie Inc. (ABBV) investors include: 1. Unsustainable dividend payout ratio (190%) could lead to a dividend cut. 2. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 3. Drug Manufacturers - General sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is AbbVie Inc.'s (ABBV) current debt and financial health profile: Total debt stands at $70.88B. The current ratio is 0.81, which is below 1.0 and may indicate short-term liquidity concerns. The quick ratio is 0.49. The company holds $6.57B in cash and equivalents. Free cash flow is positive at $16.87B, providing a cushion for debt servicing and shareholder returns.